전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved173 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleBeijing BiotechPhase 2

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

Malignant Pleural Mesotheliomas · Malignant Pleural Mesotheliomas

#MalignantPleuralMesotheliomas#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-D (EB-PT-CAR-NK-D)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

EB-SELECT Single-Target CAR-NK Cells (EB-SELECT Single-Target CAR-NK Cells)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleEssen BiotechPhase 2

pembrolizumab (Keytruda, EBNK-001 + IL-15 + Pembrolizumab)

Cancer; Sarcoma · Cancer

#Cancer#Antibody#Phase2#monoclonal-antibody#Sarcoma+1
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSolving Kids' CancerPhase 1

Ex vivo Expanded and Activated Haploidentical Donor NK Cells (Ex vivo Expanded and Activated Haploidentical Donor NK Cells)

Neuroblastoma; Relapsed Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

Expanded CB-NK cells (Expanded CB-NK cells)

Colon Cancer; Resected Stage · Colon Cancer

#ColonCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleInstitut für Klinische Krebsfor…Phase 3

trastuzumab (Herceptin, FLOT + Herceptin/Pertuzumab)

Stomach Cancer; Gastroesophageal Junction Cancer · Stomach Cancer

#StomachCancer#Antibody#Phase3#monoclonal-antibody#GastroesophagealJunctionCancer+1
Trials 1Status Active
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 2

GEM/DOX + TGFBi expanded NK cells (GEM/DOX + TGFBi expanded NK cells)

Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

adalimumab biosimilar (GP2017, GP2017 (adalimumab biosimilar))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting

6 / 9 pages

← PreviousNext →